OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

Bilateral Nasal Polyposis Clinical Trial

Official title:

16-Week Randomized Double-Blind Placebo Controlled Parallel-Group Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day in Adolescents With Bilateral Nasal Polyps Followed With 12-Week Open-Label Treatment Phase

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03747458
• Other study ID #: OPN-FLU-NP-3103
• Status: Recruiting
• Phase: Phase 3
• Start date: December 31, 2018
• Est. completion date: March 2026

Study information

• Verified date: September 2023
• Source: Optinose US Inc.
• Contact: Kim Koob
• Phone: 215-485-1465
• Email: kim.koob[@]optinose.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 120 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 2:1 ratio (OPN-375 186 μg: Placebo). For the PK sub-study, up to 14 subjects will be enrolled to obtain 10 completers.

Description:

The primary objective of this study is to evaluate the efficacy of intranasal administration of OPN-375 186 μg Twice a Day (BID) versus placebo in adolescents with bilateral nasal polyposis and nasal congestion by analyzing the reduction of nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning diary symptom scores and the reduction in total polyp grade at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: March 2026
• Est. primary completion date: March 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Male or female subjects aged 12 to 17 years, inclusive, at time of Visit 1 (Screening).

2. Female subjects, if sexually active, must:

1. be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or

2. be surgically sterile, (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or

3. or agree to abstinence.

3. Ability to read and speak English

4. All female subjects not documented to be infertile (e.g., infertility due to congenital abnormality or surgical sterilization) must have a negative serum or urine beta-human chorionic gonadotropin (ß-hCG) at Visit 1 (Screening) and a negative urine pregnancy test at the Visit 2 (Day 1/Randomization/Baseline)

5. Must have bilateral nasal polyposis with a grade of 1 to 3 in each of the nasal cavities as determined by a nasal polyp grading scale score measured by nasoendoscopy at Visit 1 (Screening)

6. Must report at least mild symptoms of nasal congestion/obstruction as demonstrated by an average morning nasal congestion/obstruction score of at least 1.0 over the last 7 days of the run-in period (Subjects not meeting this inclusion criterion may be re-screened once after at least 4 weeks.)

7. Subjects with comorbid asthma must be stable, defined as no exacerbations (e.g., no emergency room visits, hospitalization, or oral or parenteral steroid use) within the 3 months before Visit 1 (Screening). Subjects who received inhaled corticosteroids are required to be on no more than a moderate dosage regimen as defined by 2005 Global Initiative for Asthma Guidelines (GINA) for 1 month before Visit 1 (Screening) and to be expected to remain on it throughout the study. Visit 1 (Screening)

8. Must be able to cease treatment with intranasal medications including, but not limited to, intranasal oxymetazoline or any other decongestants, intranasal antihistamines, intranasal steroids, intranasal sodium cromolyn, nasal atropine, nasal ipratropium bromide, as well as inhaled corticosteroids (except permitted doses listed above for asthma) at Visit 1 (Screening). (Note: intranasal antibiotics and saline are permissible)

9. If taking oral antihistamines, must be on a stable regimen for at least 2 weeks prior to the Visit 1 (Screening), and agree to not change the dose of these medications until after Visit 3 (Week 4) of the study.

10. Subject (with assistance from parent or legal guardian if needed) must demonstrate the ability to correctly complete the daily diary during the run-in period to be eligible for randomization.

11. Must demonstrate correct use of the demo exhalation delivery system (EDS).

12. Must be capable, in the opinion of the investigator, of providing assent and the appropriate parent(s) or guardian must provide an informed consent to participate in the study.

Exclusion Criteria:

1. Pregnancy or lactation

2. Has a history of cystic fibrosis

3. Have used XHANCE® (fluticasone propionate) nasal spray within the past 2 months

4. Inability to achieve bilateral nasal airflow for any reason, including nasal septum deviation

5. Inability to examine both nasal cavities for any reason, including severe nasal septum deviation

6. Have history of nasal septum erosion, ulceration or perforation or evidence of such lesion on Visit 1 (Screening) nasal examination/nasoendoscopy

7. Other significant nasal pathology or abnormal anatomy

8. Has had any episode of epistaxis with frank bleeding in the 3 months before Visit 1 (Screening)

9. History of more than 5 sinus or nasal surgeries for either nasal polyps or nasal/sinus inflammation (lifetime) Visit 1 (Screening)

10. Have had any surgery on the nasal septum

11. History of sinus or nasal surgery within 6 months before Visit 1 (Screening)

12. History of any surgical procedure that prevents the ability to accurately to diagnose or grade polyps if the subject requires nasoendoscopy

13. Current, ongoing rhinitis medicamentosa (rebound rhinitis)

14. Have significant oral structural abnormalities (e.g., a cleft palate)

15. History of Churg-Strauss syndrome or dyskinetic ciliary syndromes

16. Purulent nasal infection (recent fever or symptoms of lethargy), acute sinusitis, or upper respiratory tract infection within 2 weeks before Visit 1 (Screening). Potential subjects presenting with one of these infections may be rescreened after 4 weeks

17. Have an allergy, hypersensitivity, or contraindication to corticosteroids or steroids

18. Have an allergy or hypersensitivity to any excipients in study drug

19. Exposure to any glucocorticoid treatment with potential for systemic effects (e.g., oral or parenteral steroids, high dose topical steroids) within 1 month before Visit 1 (Screening); except as noted in inclusion criteria for subjects with comorbid asthma

20. Currently receiving Nucala (mepolizumab), Cinquair (reslizumab), Dupixent (dupilumab), or Omalizumab (Xolair®) (note patients should not be removed from their therapy for the sole purpose of study participation)

21. Have nasal or oral candidiasis

22. Have taken a potent CYP3A4-inhibitor within 14 days before Visit 1 (Screening)

23. Any serious or unstable concurrent disease, psychiatric disorder, or any significant concomitant medical condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study, or pose a specific risk to the subject due to study participation

24. History or current diagnosis of glaucoma or ocular hypertension (intraocular pressure >21 mmHg)

25. History of intraocular pressure elevation on any form of steroid therapy

26. Current diagnosis of the presence (in either eye) of a cataract of Grade 1 or greater as defined on the Eye Examination Worksheet OR, less than a Grade 1 cataract with associated visual impairment

27. A recent (within 1 year of Visit 1 (Screening) clinically significant history of drug or alcohol use, abuse, or dependence)

28. Positive urine drug screen at Visit 1 (Screening) for stimulants, opioids, or cocaine

29. Have participated in an investigational drug clinical trial within 30 days of Visit 1 (Screening)

30. Parents, guardian or caregivers of the subject who are employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator

Related Conditions & MeSH terms

• Bilateral Nasal Polyposis
• Nasal Polyps

Intervention

Drug:
• OPN-375
OPN-375, BID

Locations

Country	Name	City	State
United States	Children's Healthcare of Atlanta	Atlanta	Georgia
United States	Children's Hospital Colorado	Aurora	Colorado
United States	Kern Research	Bakersfield	California
United States	Clinical Research Center of Alabama	Birmingham	Alabama
United States	MUSC Department of Otolaryngology, Head and Neck Surgery	Charleston	South Carolina
United States	Allergy Asthma & Immunology Research Institute	Charlotte	North Carolina
United States	Chicago ENT	Chicago	Illinois
United States	Rush University Medical Center - Department of Otorhinolaryngology	Chicago	Illinois
United States	University of Missouri Medical Center	Columbia	Missouri
United States	Central California Clinical Research	Fresno	California
United States	Arizona Allergy and Immunology Research	Gilbert	Arizona
United States	San Tan Allergy & Asthma	Gilbert	Arizona
United States	Nemours Children's Specialty Care	Jacksonville	Florida
United States	Kentuckiana ENT	Louisville	Kentucky
United States	Children's Minnesota	Minneapolis	Minnesota
United States	West Virginia University	Morgantown	West Virginia
United States	Yale School of Medicine, Section of Otolaryngology	New Haven	Connecticut
United States	Ochsner Medical Center, Otorhinolaryngology Department	New Orleans	Louisiana
United States	Eastern Virginia Medical School - Otolaryngology	Norfolk	Virginia
United States	Allergy, Asthma & Clinical Research Center	Oklahoma City	Oklahoma
United States	Children's Hospital of Orange County	Orange	California
United States	Carolina ENT	Orangeburg	South Carolina
United States	Allergy and Asthma Consultants	Redwood City	California
United States	University of Rochester	Rochester	New York
United States	Sacramento ENT	Roseville	California
United States	University of Utah	Salt Lake City	Utah
United States	STAAMP Research	San Antonio	Texas
United States	Spokane ENT	Spokane Valley	Washington
United States	Vital Prospects Clinical Research Institute, P.C.	Tulsa	Oklahoma

Sponsors (1)

Lead Sponsor	Collaborator
Optinose US Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Assessment of safety from physical examination-measuring weight	Assessment of safety from physical examination-weight measured in kg or lb	Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Other	Assessment of safety from physical examination-measuring height	Assessment of safety from physical examination-height measured in cm or in	Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Other	Assessment of safety by recording the severity of AEs	Assessment of safety by measuring severity of AEs using scale with 1=mild, 2=moderate, 3=severe	16 Weeks
Other	Assessment of safety by nasal examination	Assessed in nasal examination worksheet which includes recording the presence of any epistaxis, septal erosion/perforation, ulceration/erosion of area other than septum. If present, the nostril location is also recorded, along with severity, and if there is any relation to an injury or trauma	16 Weeks
Other	Assessment of safety by ocular examination-visual acuity	Assessment of safety by performing visual acuity test assessment using eye chart. Separate recording for each eye in the form of a fraction, 20/...	Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Other	Assessment of safety by ocular examination-Intraocular Pressure	Assessment of safety by averaging intraocular pressure measurement of 2 or 3 measurements to determine if it is >21mmHg	Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Other	Assessment of safety by ocular examination-Cataract Evaluation	Cataracts should be again assessed present or absent, If cataract is diagnosed, cataract type per localization should be specified and cataract should be graded 1=mild, 2=moderate, 3=pronounced, 4=severe	Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)
Other	Assessment of safety measuring vital signs (blood pressure)	Includes systolic and diastolic blood pressure measurements in millimeter of mercury (mmHg)	16 Weeks
Other	Assessment of safety measuring vital signs (pulse)	measure pulse in beats per minute (bpm)	16 Weeks
Other	Assessment for safety from the collection of information for concomitant medications usage		16 Weeks
Other	Assessment of pharmacokinetics - AUC(0-t) (pg*hr/mL)	PK Laboratory to determine the concentrations of fluticasone propionate [AUC(0-t) (pg*hr/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.	8 hours, 1 to 2 weeks before randomization
Other	Assessment of pharmacokinetics - AUC(0-8) (pg*hr/mL)	PK Laboratory to determine the concentrations of fluticasone propionate [AUC(0-8) (pg*hr/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.	8 hours, 1 to 2 weeks before randomization
Other	Assessment of pharmacokinetics - AUCex (%)	PK Laboratory to determine the concentrations of fluticasone propionate [AUCex (%) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.	8 hours, 1 to 2 weeks before randomization
Other	Assessment of pharmacokinetics - Cmax (pg/mL)	PK Laboratory to determine the concentrations of fluticasone propionate [Cmax (pg/mL) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.	8 hours, 1 to 2 weeks before randomization
Other	Assessment of pharmacokinetics - tmax (h)	PK Laboratory to determine the concentrations of fluticasone propionate [tmax (h) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.	8 hours, 1 to 2 weeks before randomization
Other	Assessment of pharmacokinetics - t1/2 (h)	PK Laboratory to determine the concentrations of fluticasone propionate [t1/2 (h) measurement] in human plasma using high performance liquid chromatography (HPLC) with mass spectrometric detection. Approximately 5 mL of blood is collected from each subject at 10 different timepoints over an 8-hour period, for a total of 50 mL. The timepoints are: Pre-dose; 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 3 hours, 6 hours and 8 hours post-dose.	8 hours, 1 to 2 weeks before randomization
Primary	Change in nasal congestion/obstruction symptoms (mild, moderate, severe) at the end of Week 4	Change in nasal congestion/obstruction symptoms at the end of Week 4 measured by the 7-day average instantaneous morning (AM) diary symptom scores (ADS7-IA). The nasal symptom scale is what is used to score the nasal congestion/obstruction score, which is recorded in the diary. Nasal symptom scale is graded on a scale of 0=no symptom, 1=mild symptom, 2=moderate symptom, 3=severe symptom.	4 Weeks
Primary	Mean change from baseline at Week 16 in total polyp grade	Change in total polyp grade (sum of scores from both nasal cavities) at Week 16 as determined by a nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril	16 Weeks
Secondary	Change in bilateral polyp grade over time	nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril	16 Weeks
Secondary	Percentage of subjects with a =1 point improvement in polyp grade	nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril	16 Weeks
Secondary	Percentage of subject with a grade of 0 on at least one side of the nose	nasal polyp grading scale score measured using a 0 to 6 point severity grading scale, with 0 (no polyps) to 3 (severe polyps) points per nostril	16 Weeks
Secondary	Change in diary symptom scores for the symptoms of nasal congestion/obstruction, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)	The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)	16 Weeks
Secondary	Change in diary symptom scores for the symptoms of rhinorrhea, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)	The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)	16 Weeks
Secondary	Change in diary symptom scores for the symptoms of facial pain or pressure, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)	The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)	16 Weeks
Secondary	Change in diary symptom scores for the sense of smell, measured as instantaneous and reflective scores for the morning and the afternoon (AM and PM scores)	Sense of smell will be scored on a scale from 0 (normal) to 3 (absent, no sense of smell)	16 Weeks
Secondary	The proportions of subjects who have reductions in the AM and PM, instantaneous and reflective, average nasal congestion/obstruction symptom scores by 0.5 or more points from baseline to the end of the double-blind treatment phase	The Nasal Symptom Scale is graded on a scale of 0 (no symptom) to 3 (Severe symptom)	16 Weeks
Secondary	Subjects will assess their global impression of change since starting the study drug using the PGIC scale	Subject global impression of change will be assessed using a subject-completed PGIC scale, with a single question rated from 1=very much improved to 7=very much worse	16 Weeks
Secondary	Subjects will assess their change in quality of life since starting the study drug using the quality of life questionnaire (SN-5).	Quality of life assessment using the SN-5 Questionnaire, a subject/parent-completed questionnaire that consists of 5 specific symptoms-related questions (answered on a 7-point Likert scale on the frequency of symptoms, 1=none of the time, 7=all of the time), and 1 general overall quality of life question (answered on a visual analog scale from 0 to 10, worst to best).	16 Weeks
Secondary	Proportion of subjects eligible for surgical intervention (independent of actual surgery performed)	The assessment criteria are as follows: Subject has had moderate symptoms of congestion from nasal polyposis for at least 3 months.; Subject continues to suffer from at least moderate symptoms despite use of topical steroids at conventional doses for at least 6 weeks.; Subject continues to suffer from at least moderate symptoms despite use (or previous use) of saline lavage for at least 6 weeks.; Subject has endoscopically visualized bilateral nasal polyposis of at least moderate severity (nasal polyp grading score > 2 in at least 1 nostril). Also assess each subject's eligibility for surgery based on specific of criteria (see Section 12) independent of whether the subject actually undergoes surgery.	Visit 1 (Screening) and Visit 6 (Week 16/ End of Double-Blind/Early Termination)